BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20200101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211125T190000 DTEND;TZID=Africa/Nairobi:20211125T203000 DTSTAMP:20260424T035859 CREATED:20211104T080530Z LAST-MODIFIED:20211207T072429Z UID:6769-1637866800-1637872200@kesho-kenya.org SUMMARY:Paediatric Oncology in Kenya: Current Landscape and Future Perspectives DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSpeaker Profiles: \nDr. Gilbert Olbara \nDr. Olbara is a Paediatrician/Paediatric Hematology Oncology Fellow at the Moi Teaching Referral Hospital/ Moi University. He holds a Bachelor’s degree in Medicine and Surgery from Moi University and a Master’s in Child Health and Paediatrics from the same institution. \nDr. Olbara is also a clinical researcher at Ampath Oncology. \nHe has an interest in child health and development and with a lifetime goal of contributing to improved treatment outcomes of childhood cancer in low resource settings through translational research and knowledge dissemination \nDr. Festus Njuguna \nDr. Njuguna is a Lecturer at Moi University\, School of medicine\, Department of child Health and Paediatrics; he is also the Head of Paediatric haemato-oncology unit at Moi Teaching and Referral Hospital. He attained his Bachelor’s degree in Medicine and Surgery from Moi University and a Master’s degree in Medicine (Paediatrics) from the same institution. \nDr. Njuguna has several publications in peer reviewed journals. \nModerator: DR. IRENE NZAMU \nDr. Nzamu is a Pediatric Hematologist Oncologist and Head\, Pediatric Hemato Oncology Unit\, Kenyatta National Hospital. She pursued her undergraduate training (MBChB) & postgraduate training (M.MED) at the University of Nairobi. Dr. Nzamu did her Fellowship in Pediatric Hematology & Oncology at Makerere University in collaboration with Baylor College of Medicine & Global HOPE Texas Children’s Hospital. She is passionate about offering evidence-based\, affordable care for children with cancer & blood diseases in our resource-limited settings. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/childhood-cancer/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/11/web.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211111T190000 DTEND;TZID=Africa/Nairobi:20211111T203000 DTSTAMP:20260424T035859 CREATED:20211104T080411Z LAST-MODIFIED:20220118T080513Z UID:6766-1636657200-1636662600@kesho-kenya.org SUMMARY:Multicentric Castleman's Disease DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nAnne Mwirigi MBChB\, MRCP\, FRCPath (UK) \nDr Mwirigi is a consultant haematologist working at the Aga Khan University Hospital in Nairobi\, Kenya. She obtained her undergraduate MBChB from the University of Glasgow in 2002. After her house jobs and a medical rotation in Glasgow\, she moved to London in February 2007. \nHer career in Haematology began as a senior house officer at King’s College Hospital\, following which she was accepted on the Guy’s and St Thomas’ NHS Trust Specialist Registrar Rotation in 2009. She obtained her certificate of completion of training in 2014\, and thereafter took on consultant haematologist positions for a period of two and a half years at both Guy’s and St Thomas’ and King’s College Hospitals. \nDr Mwirigi has a passion for haematology and always planned to practice haematology in her country of birth\, Kenya. Since moving back in December 2016\, she has engaged with haematopathologists and clinical haematologists in the region\, and is involved collaborative ventures aimed at improving the quality of haematology services in Kenya. She was a key member of the scientific committee which organised the Haematology and Oncology Society of Africa 3rd inaugural conference held in Nairobi in August 2017. \nDr.  Laura Chebet Kirui MBChB BSc MRCP FRCPath \nDr. Laura Kirui is a Consultant Haemato-Oncologist\, in the Department of Haematology-Oncology at Aga Khan University Hospital Nairobi. \nAlongside her work in acute leukemia\, lymphoma and myeloma\, she has a special interest in haemostasis and thrombosis and obstetric haematology. In her role as Clinical Lead for haemostasis and thrombosis she is working to expand this service at AKUHN with new dedicated clinics\, guidelines and expanded laboratory testing. \nPrior to this Dr. Kirui was a Consultant Haematologist/Haemato-oncologist at the North Middlesex University Hospital\, UK working in malignant and benign haematology and heading the Transfusion and Haematology laboratory. \nDr. Kirui underwent specialist training in Haematology at University College London Hospital where she received her Certificate of Completion of Training. \nShe is a Fellow of the Royal College of Pathologist\, UK and a Member of the Royal College of Physicians and has a Bachelor’s of Medicine and Surgery from the University of Leeds\, UK with an intercalated BSc in International Health. \nModerator: Dr. Fredrick Otieno Okinyi \nDr.Okinyi is a lecturer  of haematology at the school of medicine\, university of Nairobi  and a consultant  at Kenyatta National Hospital. He has 18years of practice of medicine in various regions in Kenya  and seven years of teaching and research in Haematology. He has  received  trainings   and fellowship  in various  aspects of haematology mainly oncology\, palliative care\, clinical haematology and hematopathology in diverse centers in the U.S.A. He is also the current chairman  of  chairman of Kenya sickle cell federation. He has participated in the in research  and development of  guidelines for clinical practice in Kenya \nHe holds a Bachelor’s degree in Medicine & Surgery from Moi University\, a diploma in Forensic Pathology from the University of Witwatersrand. Dr. Okinyi also holds a Master’s degree in Human Pathology from the University of Nairobi. He is a fellow of City of Hope National Hospital\, California. \nHis areas of interest are Sickle Cell disease\, Aplastic anemias\, Thrombotic and bleeding disorders\, Leukaemias and lymphomas and Palliative oncology. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/non-hodgkins-lymphoma/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/11/WhatsApp-Image-2021-11-09-at-12.55.51.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211028T190000 DTEND;TZID=Africa/Nairobi:20211028T203000 DTSTAMP:20260424T035859 CREATED:20210930T114813Z LAST-MODIFIED:20211109T103659Z UID:6144-1635447600-1635453000@kesho-kenya.org SUMMARY:Metastatic Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nDr. Beverly ChereremDr. Cheserem is an Associate Professor and Consultant neurosurgeon at Aga Khan University Hospital. She has a sub-specialty interest in skull base surgery and pituitary; both microsurgical and endoscopic techniques. Her other interests include global health\, teaching and clinical research. \nQualifications:BM ( Honours)\, University of SouthamptonSouth London Neurosurgical training program\, UKFRCS ( Neurosurgery) – Royal College of Surgeons\, UKSkullbase (microscopic and endoscopic techniques)\, University Hospital Wales\, UKTravelling fellow of Bellaria Hospital (Italy)\, Lariboisiere Hospital (France) and UPMC (USA)Weill Cornell Global Health Fellowship based at Muhumbili Orthopaedic Institute Tanzania \n*   Fellow Royal College of Surgeons\, England (FRCS\, Eng)*   Member\, Association of Medical Educators (AOME) UK*   Member\, British Association of Surgical Oncology (BASO)*   Full Member\, Society of British Neurosurgeons (SBNS)\, UK\,*   Member\, Congress of Neurological Surgeons (CNS)*   Member\, Kenya Medical Association (KMA) \nLeadership positions:Chairperson\, Kenya Association of women Surgeons (KAWS)Vice-chair\, Scientific Committee\, Surgical Society of Kenya (SSK)Committee member\, Global Surgery Committee\, Surgical Society of Kenya \nDr. Cheserem has been awarded the 2021\, Future Women Leaders Fellowship Award by the Congress of Neurologocal Surgeons (CNS)\, US \nDr. Ahmed KomenDr. Ahmed Komen is a Clinical Radiation Oncologist. He is a fellow of College of Medicine South Africa and holds a Master of Medicine in Radiation Oncology from the University of the Witwatersrand\, Johannesburg\, South Africa. He is a Consultant at Kenyatta National Hospital and a part time faculty member at Aga Khan University Hospital. \nDr. Komen is an active member of various multi-disciplinary tumour boards and the Kenya Society of Haematology and Oncology (KESHO). \nModerator: Dr. Asim Jamal Shaikh Dr. Jamal Shaikh is an Associate Professor\, Consultant Medical Oncologist and Division Chief of medical oncology\, Department of Hematology and Oncology\, at The Aga Khan university Hospital Nairobi.Dr. Shaikh received his internal Medicine residency and medical oncology fellowship training from Pakistan. He is a Fellow of College of Physicians and Surgeons Pakistan in the subjects of internal medicine and medical oncology both\, and The Royal college of Physicians UK.Dr. Shaikh has a Leadership Diploma from Harvard Kennedy School of Executive education USA\, and the Graduate School of Media at The Aga Khan University.  He is actively involved in clinical service and research. His focus of clinical practice is in solid tumors.  He has published widely and specially recently on genomic and clinical aspects of Kenyan and East African women with breast cancer.He Leads the Kenyan Metastatic breast cancer network (www.kmbcn.org ) in Kenya. He is the recipient of several international collaborative grants as clinical investigator for oncology research including the SPARC grant from the UICC.  He has laid the foundation of medical oncology fellowship programs at the Aga Khan University in Nairobi\, and with his academic interests supervises several master level students to their thesis related to cancer studies. \n  \n[/vc_column_text] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/metastatic-breast-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/webinar-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211021T190000 DTEND;TZID=Africa/Nairobi:20211021T203000 DTSTAMP:20260424T035859 CREATED:20210930T114540Z LAST-MODIFIED:20211104T094816Z UID:6141-1634842800-1634848200@kesho-kenya.org SUMMARY:New Innovations in Breast Cancer Diagnosis and Screening DESCRIPTION:[vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nDr. Shahin Sayed \nDr. Sayed is Associate Professor & Consultant in Anatomical Pathology and Cytology\, in the Department of Pathology\, Medical College\, Aga Khan University\, and the current Chair and Laboratory Director of Pathology at AKUH\, N \nDr. Sayed graduated from the University of Nairobi with a Bachelor of Medicine and Surgery degree. She holds a Master of Medicine in General Pathology from the University of Nairobi where she was awarded the best student in Pathology prize. She is a Fellow of the Royal College of Pathologists\, United Kingdom\, and a Fellow of the College of Pathologists of East Central and Southern Africa. \nDr. Sayed is the Secretary-General of the College of Pathologists of East Central and Southern Africa\, Chair of the Academic Committee of the Senate – East Central and Southern African (ECSA) College of Health Sciences\, Chair of the Board of Directors of African Strategies for Advancing Pathology (ASAP\, co-chair Technical Working Group (TWG) on Diagnostics for the Cancer Control Programme – Ministry of Health\, Kenya (MoH). \nShe is also a steering committee member and Commissioner for the Lancet Commission on Diagnostics and a member of the Lancet Oncology Commission for Sub-Saharan Africa. She has also been a recent member of the WHO-SAGE IVD Committee (2019-2020). Dr. Sayed is a member of the United States and Canadian Academy of Pathology (USCAP) and the American Society of Clinical Oncology (ASCO). \nDr. Sayed is in charge of the breast service at AKUHN. Her research interest span oncopathology with a special focus on breast cancer and solid haematolymphoid malignancies. She has several grants and peer-reviewed publications in her area of research interest. She has also led research initiatives and interventions that have developed a sustainable model of community-based engagement to improve breast cancer screening and diagnosis. \nDr. Rose Ndumia \nDr. Ndumia is an assistant professor and consultant radiologist in Breast Imaging. She obtained her medical degree from the University of Nairobi and her Radiology Residency in Radiology at the Aga Khan University Hospital\, Nairobi. In 2017\, she completed a one-year fellowship in diagnostic and interventional breast imaging from the Marleen Greenebaum Diagnostic Breast Centre\, Hadassah University Hospital in Jerusalem\, Israel with observership experience at the Memorial Sloan Kettering Cancer Centre’s Breast Imaging Center in New York. She has keen interests in breast imaging\, medical education\, and research. \nShe is the section head of breast imaging and is actively involved in the acquisition of state-of-the-art imaging equipment and initiation of new procedures such as Digital mammography with 3D tomosynthesis\, Stereotactic biopsies\, and Vacuum Assisted Biopsy (VAB)\, and Occult lesion localizations. She takes the Radiology lead in the weekly multidisciplinary breast tumor board meetings and is the current Program Director for the Radiology Residency Training Program. \nHer research interests are mainly in breast cancer\, assessment of mammographic breast density\, global health\, and medical education. At a policy level\, she has worked in conjunction with the Kenya Association of Radiologists to develop national breast cancer screening guidelines as well as imaging guidelines that when implemented should improve overall patient outcomes. \nModerator: Dr. Mercy Gatua. \nDr. Gatua is a Medical Oncologist at the Kenyatta University Teaching Research and Referral Hospital. She received her Medical Oncology Fellowship from the University of Nairobi in 2019. Prior to that\, she earned her MMED in Internal Medicine at the same university (UON). Her main interests are in the management of acute leukemia’s\, GI malignancies and Cervical Cancer. She also has an interest in research geared to understanding the genetic basis of cancer. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/new-innovations-in-breast-cancer-diagnosis-and-screening/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/webinar-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211014T190000 DTEND;TZID=Africa/Nairobi:20211014T203000 DTSTAMP:20260424T035859 CREATED:20210930T113923Z LAST-MODIFIED:20211024T155952Z UID:6138-1634238000-1634243400@kesho-kenya.org SUMMARY:Breast Cancer Considerations in a Reproductive Age-Group DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILE: \nDr. Gladwell Gichuru-Kiarie \nDr. Gladwell Kiarie graduated with MBChB (Bachelor of Medicine and Bachelor of Surgery) degrees from The University of Nairobi and went ahead to receive her post-graduate degree in Internal Medicine from the same institution. After receiving her undergraduate degrees\, she did her internship at the Kenyatta National Hospital before proceeding to pursue her fellowship in Medical Oncology in London\, England. \nAfter sub-specialization in Medical Oncology\, she returned to Kenya where she was one of the founding members of the Oncology Unit at the Aga Khan University Hospital and was also part of the team that set up the first Kenyatta National Hospital Tumor Board in 2007 that involved multiple personnel from surgical and medical departments. \nShe then joined the University of Nairobi in the Clinical Medicine Department as a Senior Lecturer. Soon afterward\, she enrolled for a PhD program with the Bart’s Cancer Institute under the supervision of Professor John Gribben. She recently received Fellowship to the Royal College of Physicians of Edinburgh (FRCPE). \nShe currently runs a private practice at The Nairobi Hospital and also reviews patients at other leading hospitals in Nairobi and Nakuru including The Aga Khan University Hospital\, MP Shah Hospital\, and Avenue Hospital. She also serves in the Kenya Medical Practitioners and Dentists Board since her appointment in 2015 to the Regulatory Department of the Board. \nShe is a member of the Kenya Society of Haematology and Oncology (KESHO) where she also served as the treasurer in 2004 and is also a full member of the American Society of Clinical Oncology (ASCO) as well as European Society for Medical Oncology (ESMO). \nShe continues to be an advocate for early diagnosis of cancer and is greatly involved in programs that focus on providing easy access to basic screening services to the underprivileged including setting up oncology services at the county level. In recognition for this\, she won the Union for International Cancer Control (UICC) in 2014 for screening in poor settings. \nMODERATOR: Dr. Mohammed Ezzi \nDr. Mohammed Ezzi is a Lecturer and Consultant Medical Oncologist. He is actively involved in clinical practice\, teaching\, and cancer research at the University of Nairobi and Kenyatta National Hospital. Dr. Ezzi holds a Master’s degree in Internal Medicine from the University of Nairobi. He later did his Fellowship in Medical Oncology at the University of Nairobi. \nHe has presented at several symposia\, workshops\, and conferences both locally and internationally. He has several publications in peer-reviewed international journals. Dr. Mohammed Ezzi is a member of KESHO\, ASCO\, ESMO\, AORTIC\, and KAP. His key areas of interest include breast cancer and clinical pharmacology. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/breast-cancer-her2-positive/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/webinar.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20211007T190000 DTEND;TZID=Africa/Nairobi:20211007T203000 DTSTAMP:20260424T035859 CREATED:20210930T113608Z LAST-MODIFIED:20211024T160011Z UID:6134-1633633200-1633638600@kesho-kenya.org SUMMARY:Oligometastatic Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]SPEAKER PROFILES: \nDr. Anthony Ndiritu\nDr. Ndiritu is a Consultant Clinical Oncologist at the Kenyatta National Hospital. His main interests lie in Head and Neck Cancer\, CNS\, and Gastrointestinal tract malignancies. \nDr. Ndiritu’s research interest is in cancer of the endometrium. \nModerator: Dr. Angela McLigeyo. \nDr. McLigeyo is a licensed Physician and Medical Oncologist practicing in Kenya. She has a Master of Medicine in Internal Medicine from the University of Nairobi\, a M.Sc. in Clinical Oncology from Ulm University (Germany)\, and a Fellowship in Medical Oncology from the University of Nairobi. In addition\, she obtained a 5-year board certification in Medical Oncology from ESMO in 2019. \nShe has over 17 years of experience in hospital and clinical settings. \nHer core skills are in clinical decision-making in internal medicine and oncology\, conducting training\, streamlining medical education\, and conducting research as well as participation in the development of treatment guidelines and protocols. \nShe currently provides comprehensive oncology healthcare at both public and private health facilities\, conducts research in oncology and internal medicine when opportunities arise and is engaged in teaching internal medicine and oncology at the Kenyatta University. She has authored several research articles in peer-reviewed journals and presented abstracts at several conferences.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/breast-cancer-hormone-positive/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/BREAST.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210930T190000 DTEND;TZID=Africa/Nairobi:20210930T203000 DTSTAMP:20260424T035859 CREATED:20210927T102656Z LAST-MODIFIED:20211024T151722Z UID:6123-1633028400-1633033800@kesho-kenya.org SUMMARY:Prostate Cancer; Metastatic Adenocarcinoma DESCRIPTION:[vc_row][vc_column][vc_column_text]SPEAKER PROFILES: \nDr. Manel Haj Mansour \nDr. Mansour is a consultant physician and board-certified medical oncologist currently working at the Aga Khan University Hospital. She was formerly a consultant medical oncologist at Texas Cancer Centre\, Nairobi\, and also worked as a consultant medical oncologist and a lecturer at Abderrahmen University Hospital\, Tunisia. \nDr. Mansour graduated from the Faculty of Medicine of Tunis in 2012 and completed medical oncology residency in 2017. \nShe holds: \n\nA certificate of completion of Oncologic Science Course online in Breast Cancer treatments from The Africa Breast University.\n\n\nA certificate of medical oncology training on XXXIIth course antitumor chemotherapy and cancer medical treatment at Gustave Roussy Institute Paris\, France.\n\n\nA post-graduate certificate in Prevention and Palliative Care in Oncology\, Faculty of Medicine of Sousse.\nA post-graduate certificate in Thoracic Oncology\, Faculty of Medicine of Tunis.\nA post-graduate certificate in Breast Disease\, Faculty of Medicine of Tunis. She is a member of ESMO\, ASCO\, STOM (Tunisian Society of Medical Oncology)\, and KESHO. Her areas of interest include breast cancer\, lung cancer\, gastrointestinal cancers\, gynecological and genitourinary cancers.\n\nModerator: Dr. Edward Chege Ng’ang’a MBChB\, MMed \nDr. Chege obtained his medical degree from Moi University School of Medicine in 2008 and completed residency training in radiology at Aga Khan University Hospital\, Nairobi in 2016. He then undertook a one-year subspecialist training in oncology imaging at the Royal Marsden NHS Trust in London UK. He was then appointed consultant radiologist at AKUH\, where he is the radiology lead in body cross-sectional imaging\, and section head for CT. \nDr. Chege’s interests lay mainly in cross-sectional oncology imaging\, non-vascular Interventional radiology\, and functional MR imaging[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/prostate-cancer-metastatic-adenocarcinoma/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/METASTATIC.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210928T190000 DTEND;TZID=Africa/Nairobi:20210928T203000 DTSTAMP:20260424T035859 CREATED:20210726T071458Z LAST-MODIFIED:20211024T160037Z UID:5746-1632855600-1632861000@kesho-kenya.org SUMMARY:Endometrial Cancer part 2 DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nDr. Khadija Warfa \nDr. Warfa is a Consultant Obstetrician-Gynecologist and a Gynecologic Oncologist. She completed a four-year residency in obstetrics and gynecology at Aga Khan University in 2012. On completion\, she worked as a clinical instructor in the department for a year and proceeded to the University of Calgary\, Canada for a two-year fellowship in Gynecologic Oncology. She is involved in the training and supervision of postgraduate students\, she runs various clinics at the hospital with a wide referral base from East and Central Africa. \nDr. Warfa is also involved in creating awareness in women’s cancer; she gives talks in various institutions voluntarily to educate women about cervical cancer screening\, her objective is to reduce mortality related to Gynecologic Cancers in Kenya. She is a member of the European society of gynecologic oncology (ESGO) and a member of the Kenya Society of obstetricians and gynaecologists (KOGS). \nDr. Ahmed Komen \nDr. Komen is a clinical Radiation Oncologist. He is a fellow of the College of Medicine South Africa and holds a Master of Medicine in Radiation Oncology from the University of the Witwatersrand\, Johannesburg\, South Africa. \nHe is a consultant at Kenyatta National Hospital and a part-time faculty member at Aga Khan University Hospital. \nDr. Komen is an active member of various multi-disciplinary tumour boards and the Kenya Society of Haematology and Oncology (KESHO). \nModerator: Dr. Gregory Ochieng Ganda \nDr. Ganda is a Gynaecologist Oncologist at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH). He currently runs the oncology clinic at the facility and also does his private practice at various private facilities in Kisumu including but not limited to the Bloom surgical center\, Aga Khan Hospital\, Kisumu Specialist Hospital. He runs the gynecology oncology clinic at JOOTRH on Tuesdays and splits the rest of his time in the wards and in the theatre. \nHis work as a medical officer in remote areas in Voi\, where women had bad obstetric outcomes led him to start the hot tea initiative (where women who had delivered were given hot tea and baby shawls as a motivation for hospital delivery)\, renovation and opening of the theater which led to his special recognition and Masters sponsorship. He went into Oncology after having met many patients with poor survival rates after lack of access to specialty care and wanted to make a difference. \nDr. Ganda has a Master of Medicine in Gynecology oncology from Makerere University and a fellowship in gynecology oncology from Moi University in collaboration with the University of Toronto. He previously worked at the Coast General hospital\, Ngao district hospital\, and Migori county hospital. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/endometrial-cancer-part-2/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/07/endo-part-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210923T190000 DTEND;TZID=Africa/Nairobi:20210923T203000 DTSTAMP:20260424T035859 CREATED:20210920T150733Z LAST-MODIFIED:20211024T161718Z UID:6102-1632423600-1632429000@kesho-kenya.org SUMMARY:Prostate Cancer – Surgical and Radio Aspects DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nMR PATRICK G. MBURUGUMB ChB\, MMed\, FRCS Urol.\, FEBU\, FCS\, DLS (Strasbourg) \nDr. Mburugu is a Urologist at the Kenyatta National Hospital. He is chair of both KAUS and the KAUS conference and workshop organizing committees. \nDr. Mburugu represents KAUS at the SIU uCARE research council. His interests are oncological\, laparoscopic\, and endo-urological surgery. \nDR HELENA MUSAU \nDr. Musau is a Consultant Clinical Oncologist working at Kenyatta University Teaching Research and Referral Hospital. She is also an adjunct Lecturer at the University of Nairobi\, Radiation Oncology Program. \nDr. Musau is a member of various Ministry of Health technical working groups aimed at improving access to cancer care in Kenya. She has worked in both the private and public sectors as well as managing oncology and palliative care projects at various levels over the last 13 years. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/prostate-cancer-surgical-and-radio-aspects/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/09/IMG-20210923-WA0003.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210922T190000 DTEND;TZID=Africa/Nairobi:20210922T203000 DTSTAMP:20260424T035859 CREATED:20210920T132529Z LAST-MODIFIED:20211024T160057Z UID:6092-1632337200-1632342600@kesho-kenya.org SUMMARY:Transition in Care in Haematology and Oncology DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES:\nDR. DOREEN KARIMI MUTUA \nDr. Mutua is a pediatrician whose passion for children with blood disorders and cancer was ignited during her residency training at the University of Nairobi where she noticed that most of these children had dismal outcomes due to late presentation\, lack of appropriate diagnostic and treatment facilities. Dr. Mutua is a beneficiary of a two-year training program conducted as a twinning program between Jimma University (Ethiopia) and ASLAN Project (a USA-based Non- Governmental organization) that seeks to build the capacity of low and middle-income countries in treating children with blood disorders and cancer. She completed her training in May 2018 and returned back to Kenya to establish hematology/oncology services that include centers of excellence for pediatric cancer care and comprehensive sickle cell care at the Gertrude’s Children’s Hospital. She is passionate about raising awareness on childhood cancer with regard to early detection\, establishing treatment guidelines\, and improving outcomes for Kenyan children who have cancer. She is also keen on seeing the establishment of comprehensive sickle cell centers in the country which can help reduce the morbidity and mortality of these patients. \nDR. SARAH MUMA \nDr. Sarah Muma is a Pediatric Oncologist at Kenyatta University Teaching Referral and Research Hospital (KUTRRH). She is a graduate of the University of Nairobi where she received her Bachelor’s degree (MBChB) as well as her Master’s degree in Pediatrics and Child Health. Her main interest is in developing low-cost\, high-impact models of management for children with cancer in low-income settings. Towards this\, Dr. Sarah did a fellowship in Pediatric Oncology at Frere Hospital\, Walter Sisulu University in East London\, South Africa. She then returned to Kenya to set up the Pediatric oncology service at AIC Kijabe Hospital\, which has been operational since 2015. Dr. Muma holds a Master’s degree in Advanced Oncology from Ulm University in Germany. Her hope is that every child will one day have an equal chance at fighting a cancer diagnosis irrespective of their geographic location or socioeconomic situation. \nDR. GRACE MBATIA MBChB\, MMED (Paediatrics and Child Health)\, Paediatric Haematology/Oncology & Bone MarrowTransplant (Fellowship)\, Healthcare Management (Post-graduate Dip). \nDr. Mbatia is currently serving as Full-time faculty at the Aga Khan University\, Nairobi providing clinical care to children with blood and cancer disorders as well as supporting pediatric post-graduate medical training for future paediatricians. Her core clinical interests lie in providing care to children with brain and solid tumors whereas her broader interests include supporting medical education\, health-systems research\, and the optimization of both general pediatric and pediatric blood and cancer care in resource-constrained settings. \nMR. COSMAS KIPKOECH \nCosmas Kipkoech\, MSW\, BA Psychology and Social Work. PGD counseling. Advanced Cert Counselling supervision\, Advanced Certificate Child Counselling\, and Play Therapy. He is currently based at Aga Khan University Hospital. \nDR. IRENE NZAMU \nDr. Nzamu is a Pediatric Hematologist Oncologist and Head\, Pediatric Hemato Oncology Unit\, Kenyatta National Hospital. She pursued her undergraduate training (MBChB) & postgraduate training (M.MED) at the University of Nairobi. Dr. Nzamu did her Fellowship in Pediatric Hematology & Oncology at Makerere University in collaboration with Baylor College of Medicine & Global HOPE Texas Children’s Hospital. She is passionate about offering evidence-based\, affordable care for children with cancer & blood diseases in our resource-limited settings. \nDR. MATILDA ONG’ONDI \nDr. Matilda is a Consultant Physician and Clinical Hemato-Oncologist at the Kenyatta National Hospital\, Kenya’s oldest and largest hospital. She holds a Bachelor of Medicine and Bachelor of Surgery (MBChB) degree (2005) and a Master of Medicine (MMed) degree in Internal Medicine (2010)\, both from the University of Nairobi. She is registered with the Kenya Medical Practitioners and Dentists Council as an Internal Medicine Specialist. Dr. Matilda pursued her Clinical Hemato-oncology training at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital\, Australia in 2017. In addition\, she has undertaken various short Fellowship opportunities through the following institutions: International Chronic Myeloid Leukemia Foundation (Royal Adelaide Hospital and SAHMRI Adelaide\, 2017); American Society of Hematology\, Visitor Training Program at The Cancer Therapy and Research Centre\, San Antonio Texas (2014); and Mayo Clinic\, Rochester\, Minnesota (2010). Her main interests are Multiple Myeloma; Acute Leukemia; Chronic Leukemia; and Platelet disorders. Her other interests are Psycho-Oncology and Clinical Research. She is also passionate about clinical bedside teaching and mentorship. Dr. Matilda is a member of various societies: Kenya Society of Hematologists and Oncologists (KESHO); European Hematology Association (EHA); and International Society of Thrombosis and Hemostasis (ISTH). In addition\, she served as a member of the bodies that developed the Kenya National Cancer Guidelines and NCCN Harmonized Guidelines. \n  \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/transition-in-care/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/09/transition.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210916T190000 DTEND;TZID=Africa/Nairobi:20210916T203000 DTSTAMP:20260424T035859 CREATED:20210726T071930Z LAST-MODIFIED:20211024T161432Z UID:5752-1631818800-1631824200@kesho-kenya.org SUMMARY:Management of Myelofibrosis DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES:  \nAnne Mwirigi MBChB\, MRCP\, FRCPath (UK)     \nDr. Mwirigi is a consultant haematologist working at the Aga Khan University Hospital in Nairobi\, Kenya. She obtained her undergraduate MBChB from the University of Glasgow in 2002. After her house jobs and a medical rotation in Glasgow\, she moved to London in February 2007. \nHer career in Haematology began as a senior house officer at King’s College Hospital\, following which she was accepted on the Guy’s and St Thomas’ NHS Trust Specialist Registrar Rotation in 2009. She obtained her certificate of completion of training in 2014 and thereafter took on consultant haematologist positions for a period of two and a half years at both Guy’s and St Thomas’ and King’s College Hospitals. \nDr. Mwirigi has a passion for haematology and always planned to practice haematology in her country of birth\, Kenya. Since moving back in December 2016\, she has engaged with haematopathologists and clinical haematologists in the region and is involved in collaborative ventures aimed at improving the quality of haematology services in Kenya. She was a key member of the scientific committee which organised the Haematology and Oncology Society of Africa 3rd inaugural conference held in Nairobi in August 2017. \nDr. Matilda Ong’ondi \nDr. Matilda is a Consultant Physician and Clinical Hemato-Oncologist at the Kenyatta National Teaching and Referral Hospital\, Kenya’s oldest and largest hospital. She holds a Bachelor of Medicine and Bachelor of Surgery (MBChB) degree (2005) and a Master of Medicine (MMed) degree in Internal Medicine (2010)\, both from the University of Nairobi. She is registered with the Kenya Medical Practitioners and Dentists Council as an Internal Medicine Specialist. \nDr. Matilda pursued her Clinical Hemato-oncology training at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital\, Australia in 2017. In addition\, she has undertaken various short Fellowship opportunities through the following institutions: International Chronic Myeloid Leukemia Foundation (Royal Adelaide Hospital and SAHMRI Adelaide\, 2017); American Society of Hematology\, Visitor Training Program at The Cancer Therapy and Research Centre\, San Antonio Texas (2014); and Mayo Clinic\, Rochester\, Minnesota (2010). \nHer main interests are Multiple Myeloma; Acute Leukemia; Chronic Leukemia; and Platelet disorders. Her other interests are Psycho-Oncology and Clinical Research. She is also passionate about clinical bedside teaching and mentorship. \nDr. Matilda is a member of various societies: Kenya Society of Hematologists and Oncologists (KESHO); European Hematology Association (EHA); and International Society of Thrombosis and Hemostasis (ISTH). In addition\, she served as a member of the bodies that developed the Kenya National Cancer Guidelines and NCCN Harmonized Guidelines. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/haematology-bleeding-clotting/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/07/WhatsApp-Image-2021-09-13-at-3.57.24-PM.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210909T190000 DTEND;TZID=Africa/Nairobi:20210909T203000 DTSTAMP:20260424T035859 CREATED:20210726T071828Z LAST-MODIFIED:20211024T160631Z UID:5750-1631214000-1631219400@kesho-kenya.org SUMMARY:Prostate Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \n1. Dr. David K Kimani MBChB\, MMed General Surgery UON (2007) \nDr. Kimani is a Consultant Urologist at Kenyatta National Hospital in Kenya\, and Honorary Lecturer Department of Surgery at the University of Nairobi. He did his Clinical Fellowship in Urology at the Global Health Institute Chennai\, India in 2014. He has keen interests in Prostate Care and Kidney Transplantation. \nDr. Kimani is a Member of SSK\, KAUS\, and the Society for International Urologists\, (SIU)\, and the American Urological Association (AUA). \n2. Dr. Wambui Kung’uDr. Wambui Kung’u is a Clinical Oncologist at Kenyatta University\, Teaching\, Referral\, and Research Hospital. She holds a Master’s Degree in Clinical Oncology and Nuclear Medicine from Alexandria University\, Egypt.She is a member of the Kenya Society of Hematology and Oncology (KESHO)\, African Organization for Research and Training in Cancer (AORTIC)\, European Society of Medical Oncology (ESMO)\, and American Society of Clinical Oncology (ASCO). \nHer main areas of interest are Head and Neck cancers\, breast cancer\, prostate cancer\, and gastrointestinal cancer. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/prostate-cancer-2/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/07/unnamed.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210902T190000 DTEND;TZID=Africa/Nairobi:20210902T203000 DTSTAMP:20260424T035859 CREATED:20210726T071708Z LAST-MODIFIED:20211203T100724Z UID:5748-1630609200-1630614600@kesho-kenya.org SUMMARY:Liver Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text] \nSPEAKER PROFILES: \nDR RIAZ KASMANI \nDr. Riaz is currently based in Mombasa\, practicing as a Medical Oncologist. \nHe headed the Oncological department at AgaKhan Hospital\, Mombasa.  He currently has a busy practice\, with offices based at AgaKhan Hospital\, Mombasa Hospital and Mombasa Cancer Centre.  He is a visiting consultant at all the major hospitals in Mombasa\, Kenya. \nDr. Riaz has a deep interest in research and has published in renowned oncological journals and has also been a speaker in many national and international conferences. Dr.  Riaz completed his MMed in Internal Medicine at the University of Nairobi and worked as a consultant physician in the Ministry of Health before joining AgaKhan Hospital – Mombasa in 2012. \nHe then proceeded for sub-specialization in Medical Oncology to Tata Memorial Hospital – Mumbai\, India.  Tata Hospital is a world-renowned hospital and the largest and most prestigious oncology center in Asia\, with a lot of research work undergoing.  After completing his training\, Dr. Riaz worked at the oncology clinic at Kenyatta National Hospital. Dr. Riaz further did intensive training in Palliative Care at the Marie Currie Institute in Paris\, France. \nDr. Riaz is registered as a specialist in Oncology by the KMPD board. Dr. Riaz has been awarded a founding fellowship in the faculty of Internal Medicine by the East Central and Southern Africa College of Physicians (ESACOP) \nHis memberships to international organisations include ASCO\, ESMO\, AORTIC. He is also a member of KESHO\, KAP\, KMA and holds various honorary posts in KMA and KAP. \nDr. Karan R. K. Gandhi \nConsultant General and Hepatobiliary Surgeon\, Full-time faculty \nDepartment of Surgery\, Aga Khan University Hospital\, Nairobi \nDr. Gandhi graduated from The University of Nairobi to receive his medical degree in 2009 and did a year of internship at the Aga Khan University Hospital\, Nairobi (AKUH\, N) in 2010. He began his surgical training at the University of Nairobi in 2011 and then moved to the University of Cape Town in 2013. He qualified as a Fellow of the College of Surgeons of South Africa in 2018 and then went on to complete his subspecialist certificate training in Surgical Gastroenterology\, specifically Hepato-Pancreatico-Biliary (HPB) Surgery\, in 2020. He also received a Masters degree in Surgery (MMed) from the University of Cape Town in 2020. In the same year\, Dr. Gandhi was also selected to represent Sub-Saharan Africa (SSA) in the IHPBA 2020 International Fellows Retreat in Melbourne\, Australia. His main clinical interests lie in Hepatic\, Pancreatic\, and Biliary surgery\, as well as gastrointestinal surgery\, advanced endoscopy\, ERCP\, and laparoscopy. Within the realm of HPB surgery\, his primary focus has been on one of the most neglected diseases in the region\, namely hepatocellular carcinoma (HCC). In the Global Surgery 2030 document published by The Lancet Commission in 2015\, eastern\, western\, and central SSA were identified as the regions in the world with the greatest unmet needs in surgical care\, and in a strange coincidence\, these are also the regions in SSA with the highest HCC incidence. \nDr. Gandhi has recently joined the AKUHN as a full-time faculty member in the Department of General Surgery\, with a view to pioneering and developing HPB Surgery in Kenya\, East Africa\, and SSA as a whole. He sees himself as one of a new generation of HPB surgeons that have a vision of changing the situation in SSA\, where delivering a surgical service is hampered by a poorly managed and funded healthcare system\, cost of treatment\, and a shortage of healthcare professionals. With the connections made during his training and the vision and guidance of his mentors\, Dr. Gandhi looks forward to creating a network of young HPB surgeons to facilitate this important endeavour. He has helped set up and is currently involved in various multi-disciplinary team (MDT) meetings\, including a monthly Sub-Saharan HCC meeting and an international collaborative HCC meeting with Fortis Hospitals in India. He is also actively involved with the HPB service and MDT meetings at the Kenyatta National Hospital\, Kenya. \nDr. Gandhi is also passionate about teaching and training young surgeons in Kenya\, especially in the fields of laparoscopy and surgical endoscopy delivery in rural areas. He is a member of the Operating Theatre Practitioners Association of Kenya (OTPAK)\, where training workshops are organised for surgical trainees in the Kenyan College of Surgeons of East\, Central and Southern Africa (COSECSA)\, in order to train and empower them to perform basic laparoscopic surgical procedures in rural centres. His role as a faculty member at the AKUH\, N also includes supervision and training of surgical residents\, thereby promoting academia alongside clinical service delivery. He plans to set up a surgical registry database in the hospital\, which will be used to generate data\, audit practice\, and produce high-quality research that can be published in reputable peer-reviewed journals. \nWith his solid background\, training\, passion and networking\, Dr. Gandhi believes he is a key player in taking HPB surgery forward on the continent of Africa. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/liver-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/07/IMG-20210901-WA0000-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210805T190000 DTEND;TZID=Africa/Nairobi:20210805T203000 DTSTAMP:20260424T035859 CREATED:20210726T071331Z LAST-MODIFIED:20211024T152020Z UID:5744-1628190000-1628195400@kesho-kenya.org SUMMARY:Themes in the Management of Sickle Cell Disease DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave\, Clinical Pathologist\, and Haemato-Oncologist\, Medirest/ \nSponsor: Novartis \nPresenters: \n\nProf. Walter Mwanda\, professor of Hematology and blood transfusion\, University of Nairobi\n\nSickle cell disease (SCD) results from glutamine to valine substitution in the beta-globin gene that produces hemoglobin S (HbS). Pathophysiology manifests a complex network of interdependent processes. The patients have a lower life expectancy\, with the majority in Kenya being below 12 years old. Less than 5% of SCD patients in Kenya are older than 25 years. The disease is characterized by dense\, rigid red blood cells that are easily trapped within organs and have a sluggish microcirculation. Haemolysis is a common manifestation in acute and chronic states. The HbS polymerizes when exposed to reduced oxygenation. This causes deformation and damage to the red blood cells (RBCs) membrane\, resulting in intravascular and extravascular hemolysis. The sickle RBCs block blood flow in capillaries and small vessels\, causing acute pain in the patients. The immediate effects of hemolysis include loss of RBC which causes anemia\, increased levels of toxic heme from the released hemoglobin\, which depletes plasma haptoglobin and hemopexin\, and saturates scavenger heme-binding proteins. Heme within the vessel interacts with inflammatory cells and the endothelium\, damaging it. Anemia is a common manifestation in SCD and may be acute or chronic. Patients with SCD are immune-compromised and should be protected from infections. For example\, vaccination together with the use of prophylactic penicillin has greatly reduced mortality and improved life expectancy in children with SCD. Vaso-occlusion is common among patients seeking treatment and is associated with adhesion of the sickle cells\, coagulation of platelets\, and activation of inflammatory cells. Hypercoagulable state of sickle cell anaemia adds to vascular occlusion. Hypercoagulation results from increased levels of thrombin and fibrin\, and a marked increase in circulating tissue factor in the endothelial cells. Blood transfusion is known to worsen coagulation. Acute and chronic forms of organ injury. may occur. The prompt identification of a sickle cell event and timely therapeutic intervention are important prognostic factors\, and delays could be life-threatening. Acute complications include acute chest syndrome\, cerebral acute events\, priapisms\, while chronic complications include pulmonary hypertension\, hepatic damage\, kidney disease\, splenomegaly\, bone joint diseases\, eye disease\, and leg ulcers. Treatment is by use of hydroxyurea\, bone marrow transplantation\, and blood transfusion. However\, transfusion therapy results in long-term iron overload complications. This is managed by the use of iron chelator drugs\, including deferoxamine and Asunra\, especially for patients on long-term blood transfusion. Various clinical trials on lentiviral gene therapy in SCD are ongoing. Gene editing by CRISPR/Cas9 to correct the beta-globin gene in hematopoietic stem cells is also undertrials[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/themes-in-the-management-of-sickle-cell-disease/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/07/sickle-cell.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210729T190000 DTEND;TZID=Africa/Nairobi:20210729T203000 DTSTAMP:20260424T035859 CREATED:20210628T082326Z LAST-MODIFIED:20211024T160150Z UID:5553-1627585200-1627590600@kesho-kenya.org SUMMARY:Lung Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Kevin Makori\, Consultant Clinical Oncologist Oasis Specialist Hospital Kisii\, Kenya & Lecturer\, Maseno University/ JOOTRH \nSponsor: Beacon \nPresenters: \n\nProf. Fredrick Chite Aswira\, Consultant Physician\, Chief Medical Oncologist & Hematologist\, Executive Director of International Cancer Institute (ICI)\n\nLung cancer is a common cancer globally according to globocan\, 2020). However\, there is no cancer registry in Kenya\, hence the statistics given are approximations. The risk factors include increasing age\, history of or current tobacco use\, exposure to cancer-causing substances in secondhand smoke\, occupational exposure\, radiation exposure\, air pollution\, family history\, infection with human immunodeficiency virus\, and beta carotene supplements in heavy smokers. There is a need for a high index of suspicion of lung cancer among the caregivers\, being the first point of contact\, as previous findings have revealed that most patients make several hospital visits before diagnosis. Consequently\, most patients are diagnosed at an advanced disease stage and have poor overall survival. The majority of the patients are aged between 60-80 years. Education and training are needed to improve diagnostics in lung cancer in Kenya. Bio-banking of tissues will improve research\, to generate knowledge mutations and signaling pathways that may be useful to define mechanisms of drug sensitivity and potential molecular targets. Efforts are geared towards characterizing\, optimally treating\, and measuring outcomes of lung cancer in Kenya. Limited awareness in the community and among health care providers is a major barrier to lung cancer management. An innovative lung cancer community outreach program targeting high-risk groups including tuberculosis patients was initiated in Kenya. A total of 412 clients were screened for lung cancer where 79 individuals were found to have lung cancer. Lung cancers are heterogenous diseases\, hence consideration of the patient’s molecular patterns should be made when initiating treatment. For immunotherapy treatment\,  PD-L1 expression remains the most important biomarker to personalize immunotherapy\, where patients with high PD-L1 expression should be treated with checkpoint inhibitor monotherapy. The addition of chemotherapy may be considered depending on symptom burden\, clinical course\, and performance status.  Immunotherapy improves outcomes for patients with advanced non-small-cell lung cancer. Further research and clinical trials should be done to identify more precise biomarkers and the optimal duration of immunotherapy. The high cost of drugs and the challenges with the importation of essential drugs further limits the effective management of lung cancer. Currently\, there are no patient assistance programs hence patients bear the cost of treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/lung-cancer-management/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/lung-cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210722T190000 DTEND;TZID=Africa/Nairobi:20210722T203000 DTSTAMP:20260424T035859 CREATED:20210628T082239Z LAST-MODIFIED:20211024T160159Z UID:5551-1626980400-1626985800@kesho-kenya.org SUMMARY:Practical Aspects of Immunotherapy... is Kenya Ready? DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Amina K Habib\, Medical oncologist\, Aga Khan University Hospital\, Mombasa \nSponsor: Beacon \nPresenters: \n\nDr. Andrew Odhiambo\, Consultant Physician\, and Medical Oncologist\, Head\, Thematic Unit of Medical oncology & Lecturer\,  University of Nairobi.\n\nImmunotherapy is a form of cancer treatment that uses the power of the body’s own immune system to prevent\, control\, and eliminate cancer. William Coley is known as the “father of immunotherapy”\, where he successfully used Coley’s toxin to treat cancer patients. Immune checkpoint inhibitors are the most common immunotherapies\, including PD1/PDL1 and CTLA4. The demand for immunotherapy treatment is increasing and the expertise in Kenya is growing. This treatment has a minimum toxicity profile\, where the colitis associated with immunotherapy is immune-mediated and not an infection. The high cost of treatment is a major challenge to the use of immunotherapy since the patients bear the cost of the drugs\, hence the need for the Kenyan government to work with the manufacturers to bring the prices down. Additionally\, the treatment is not available in public hospitals in Kenya\, and there is a need to lobby for their availability in public referral hospitals. There are few clinical trials in oncology in Kenya. Oncologists need to do more research to generate data and to publish the outcomes\, in addition to building capacity for clinical trials in Kenya. Aga Khan is undertaking a clinical trial that is studying biomarkers that can predict response to immunotherapies. This will guide the choice of patients who would benefit from immunotherapy treatment. Before using immunotherapy as the first line of treatment for non-small cell lung cancer\, one has to check the presence of mutations that may give inferior benefits to the patients. Immunotherapy and chemotherapy combinations have no effects on neutropenia.  Generic immunotherapy and biosimilars are also effective in the treatment of various forms of cancers. Chimeric Antigen Receptor engineered T cells (CAR T cells) are a form of immunotherapy used to treat aggressive relapsed and relapsed non-Hodgkin’s Lymphoma. Unfortunately\, they are very expensive.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/practical-aspects-of-immunotherapy/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/immunotherapy.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210715T190000 DTEND;TZID=Africa/Nairobi:20210715T203000 DTSTAMP:20260424T035859 CREATED:20210628T081946Z LAST-MODIFIED:20211024T160209Z UID:5549-1626375600-1626381000@kesho-kenya.org SUMMARY:Endometrial Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Gregory Ganda\, Gynaecology oncologist Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH Sponsor: AMRING Presenters: \n\nDr. Khadija Warfa\, Gynecologic oncologist\, Aga Khan University Hospital\nDr. Ahmed Komen\, Clinical and Radiation Oncologist\, Kenyatta National Hospital/AKUH.\n\nTo date\, many cancers are affecting the uterus. Endometrial cancers (EC) affect the endometrial lining of the uterus and are more common in North America and parts of Russia and China. They are less common in sub-Saharan Africa\, and mostly affect postmenopausal women with an average age of 64 years. Obesity is a major risk factor for EC oncogenesis.  Hereditary risk factors for EC pathogenesis include Lynch and Cowden syndromes. Proper diet and regular exercise\, use of hormonal contraception\, multiple childbirths\, and breastfeeding decrease the risk of EC. Clinical presentation of EC is mainly abnormal/postmenopausal bleeding\, while advanced disease presents with pelvic and abdominal symptoms resembling ovarian cancer. Diagnosis is by office pipelle biopsy and hysteroscopy biopsy. Women with ET >4-5mm on transvaginal ultrasound and also post-menopausal women with endometrial fluid >11mm and are asymptomatic should get a biopsy. The gold standard for imaging is MRI. The primary treatment for uterine-confined endometrial carcinoma is TH/BSO and lymph node assessment\, where sentinel node assessment has been shown to reduce complications related to complete lymphadenectomy. Molecular classification of EC is encouraged in all endometrial carcinomas\, especially in high-grade tumors. In molecular dualistic classification\, type I tumors are estrogen-dependent\, and associated with endometrial hyperplasia\, while Type II tumors are estrogen-independent and associated with endometrial atrophy with a poorer prognosis. The WHO histologic classification involves endometrial epithelial tumors and serous endometrial cancer. Clear cell carcinoma accounts for <10% of endometrial adenocarcinoma. They demonstrate molecular heterogeneity and can overlap with serous and endometrial carcinoma. Carcinosarcoma represents 5% of EC. The benefit of molecular classification is that the method is based on more objective variables and it identifies significantly more patients with favorable features that would otherwise be classified as a high intermediate risk with pathology review alone. Unlike other cancers\, FIGO staging does not determine the patient outcome\, because some of the prognostic characteristics of the disease have not been incorporated in the staging. Early presentation following post-menopausal bleeding results in a generally good prognosis but should be treated using an evidence-based protocol. Considerations for adjuvant treatment include the extent of surgery\, adequacy of the pathology report\, risk stratification\, and molecular classification. Lymphadenectomy should be considered for high intermediate-risk patients for adequate staging and optimal tailoring of adjuvant treatment. Radiotherapy can be used for definitive treatment on patients not candidates for surgery\, patients with recurrent disease\, and also for palliation. In a rural setup where resources are constrained\, an ultrasound can be done\, followed by a referral to a facility with the necessary resources and personnel.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/endometrial-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/endmetrial.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210708T190000 DTEND;TZID=Africa/Nairobi:20210708T203000 DTSTAMP:20260424T035859 CREATED:20210628T081850Z LAST-MODIFIED:20211024T160219Z UID:5547-1625770800-1625776200@kesho-kenya.org SUMMARY:Head and Neck Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Primus Ochieng\, Programme Director of MMed Radiation Oncology training at the University of Nairobi. He is both a Lecturer and a Consultant Clinical Oncologist at Kenyatta National Hospital \nSponsor: Merck \nPresenters: \n\nDr. Njoki Njiraini\, Consultant Clinical Oncologist at The Nairobi Hospital\nDr. Chege Macharia\, Head and Neck Surgeon at AIC Kijabe Hospital\n\nHead and neck cancers encompass a variety of cancers. The risk factors for their oncogenesis include lifestyle\, environmental factors\, age (over 45 years)\, and gender (which affects more males than females). To reduce the risk\, health education should focus on proper feeding habits\, human papillomavirus vaccination\, use of appropriate personal protective equipment (PPE) at places of work\, use of sunscreen by the population at risk\, and good oral hygiene\, in addition to annual dental check-ups. Local clinical examination of the tumor size is necessary. Tissue biopsy and imaging are necessary for correct staging and to select patients who would benefit from chemotherapy. Consequently\, the choice of therapy should consider patient and disease factors and the functional outcomes.  Clinical examination can give a lot of information about the patient. Proper management of head and neck (H and C) tumors is hindered by late-stage patient presentation\, socioeconomic challenges\, and resource strain on health care infrastructure. To overcome these challenges\, multidisciplinary teams (MDT) and contextualized national management guidelines have been established to help in the management of H and C cancers. Dentists are an important part of the MDT as they help in diagnosis and patients follow-up after treatment\,  to check on their dental health. Surgery for H and C cancers should preserve organs. Although reconstruction surgery is necessary\, it is more common in the west\, but not available in our African setup due to scarcity of resources. Patients who develop mucositis after radiation must be well managed since they have challenges with feeding and drinking\, hence are likely to become dehydrated and malnourished. The future of H and C management will involve training and fellowship programs and homegrown solutions. Merck is offering cetuximab (Erbitux)\, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is active in a variety of EGFR-expressing tumors.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/head-and-neck-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/head-and-neck-cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210706T190000 DTEND;TZID=Africa/Nairobi:20210706T203000 DTSTAMP:20260424T035859 CREATED:20210628T081738Z LAST-MODIFIED:20211024T160303Z UID:5545-1625598000-1625603400@kesho-kenya.org SUMMARY:The Unmet Need In Previously Untreated Stage IV CD30+ Hodgkin's Lymphoma DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nProf. N.A.O.Abinya\, Medical Oncologist\, the Nairobi Hospital Cancer Centre.\nProf. John Radford\, Professor of medical oncology\, University of Manchester\, Director of Research at the Christie NHS Foundation Trust. Both partners in the Manchester Cancer Research Centre.\n\nHodgkin lymphoma (HL) is a germinal center B cell lymphocytic lymphoma with Reed-Sternberg cells and their variants. It is less frequent than non- Hodgkin lymphoma (NHL) and constitutes 10% of all lymphomas. It is more prevalent in black males all over the world.  It has a single peak age of occurrence at 17 years and a bimodal incidence with a peak age between 15-30 years and 50-70 years. It is more frequent in cases with mixed cellular histology\, males\, children\, and older adults and is more prevalent in developing countries. Although the etiology is unknown\, immune depression\, infectious agents\, and environmental factors are associated with the disease.  Up to 40% of HL cases are associated with infection with Epstein-Barr-Virus (EBV)\, an oncovirus whose oncogenes generate a particular phenotype of the Hodgkin Reed-Sternberg (HRS) cells. HRS attracts a supportive microenvironment of immune and stromal cells\, suppressing local immune responsiveness. Furthermore\, EBV induces epigenetic changes in the host genome\, in addition to altering the composition and activity of the immune cells surrounding the HRS cells. The mechanisms of tumorigenesis involve dysregulation of several signaling networks and transcription factors including NFkB\, possibly by CD30 receptor signaling\, leading to genomic alterations affecting RS cell survival and immune evasion. Although there are no genetic defects to malignant HRS cells\, a number of molecular defects have been demonstrated. HL presentation involves a single peripheral lymph node with a centrifugal distribution and a continuous spread. Splenomegaly occurs in 50% of cases during the course of the disease. HL staging is by history\, physical examination\, blood hematology and chemistry\, bone marrow aspirate\, and biopsy and imaging. About 95% of early HL is treated while for advanced disease\, 70% of the cases are cured. Radiotherapy is now obsolete while chemotherapy is the common mode of treatment. Antibody therapies\, immunotherapies\, and immune checkpoint inhibitors mainly targeting programmed cell death 1 (PD-1) are available. However\, when used on their own\, they hardly induce a complete response; instead\, they convert HL into a chronic disease. Newer combinations of drugs are in use. Unlike in NHL\, CAR-T cells do not work in HL\, due to the absence of the target\, CD19. Brentuximab vedotin is an antibody-drug conjugate targeting CD30 and is effective as a single agent in relapsed/refractory Hodgkin lymphoma. Although EBV is associated with so many cancers\, there is no vaccine targeting this oncogene. The cost of treatment is a major challenge to many patients in developing countries. Quality of cure is also a major concern in developing as well as developed countries.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-unmet-need-in-previously-untreated-stage-iv-cd30-hodgkins-lymphoma/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/unmet.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210701T190000 DTEND;TZID=Africa/Nairobi:20210701T200000 DTSTAMP:20260424T035859 CREATED:20210628T081608Z LAST-MODIFIED:20211024T152319Z UID:5543-1625166000-1625169600@kesho-kenya.org SUMMARY:Cancer And COVID 19 DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n  \n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Mohammed Ezzi \nSponsor: AstraZeneca\, a global\, science-led\, patient-focused biopharmaceutical     company \nPresenters: \n\nDr. Mary Nyangasi\, Head of Division\, National Cancer Control Program\, Ministry of Health\, Kenya\n Dr. Catherine Nyongesa\, Clinical Oncologist\, Texas Cancer Center\, Nairobi and Kenyatta National Hospital.\n\nCancer is a major cause of morbidity/mortality\, where 70% of all cancer mortality occurs in low and middle-income countries. COVID origin remains unknown\, although the first case was reported in Wuhan\, China in 2019\, and the official name was declared in Feb 2020. The pandemic has greatly affected cancer patients\, their families\, and caregivers. Common symptoms of COVID 19 include fever\, chills\, cough\, and shortness of breath or difficulty in breathing\, fatigue\, and body aches. Control measures include cleaning of frequently used surfaces\, use of detergent or soaps and water\, disinfection\, maintaining social distance\, and wearing masks in public places. If quarantined\, stay home and monitor your health\, check if you have symptoms\, stay away from others\, especially those at a high risk of COVID infection. There is no specific report of increased incidence of COVID-19 asymptomatic infections in cancer patients\, although data from China\, the USA\, and Italy confirms a higher risk. Cancer cases are grouped into high-priority cases which are life-threatening conditions\, clinically unstable\, and require intervention. The medium-priority cases are non-critical but delayed intervention could impact the overall outcome. The low-priority cases have a stable condition; hence services can be delayed for the duration of the COVID-19 pandemic or is non-priority. COVID has drastically impacted the screening and diagnosis\, treatment\, palliative care\, and follow-up of cancer patients. Additionally\, adjustments have been made for logistics and supplies of cancer drugs and other essential commodities. To counter the effects of COVID on cancer patients\, the ministry of health listed cancer as an essential service and recommended that cancer centers remain open and encouraged telemedicine and alternative treatment. Additionally\, personal protective equipment and medicines were distributed to the regional cancer centers by use of courier services. Socioeconomic support for vulnerable cancer patients were provided through the Ministry of Labor and Social Services. The current policy guideline is for cancer programs to continue offering services following strict COVID-19 preventive measures\, and for the cancer patients to observe all the control measures. In addition\, doctors should consider scheduling treatment to avoid delays and rescheduling\, minimize outpatient visits\, and reduce hospital visits for patients on oral treatment by offering at least 3 courses. Patients can have some tests done near home\, and then call the doctor to give a report. Follow-up visits can also be delayed or the patients can visit the nearest hospitals. Also\, there is a need for increased surveillance while treating lung cancer patients and the elderly as they may have symptoms similar to those in COVID 19 patients. The caregivers and patients in cancer centers should be screened and positive cases should be referred to the relevant caregivers. Multidisciplinary tumor boards (MDTs) are encouraged in decision-making as they can discuss the benefits and risks of present therapies. Non-life threatening conditions may explore the possibilities of watchful waiting. Additionally\, oral therapies may be alternatives to chemotherapies. Adjuvant therapies are highly recommended for patients with resected high-risk diseases who are set to benefit from treatment. Late presentation is a major challenge in cancer management in the country. Vaccination of cancer patients is generally safe\, but the timing of vaccination depends on the treatment that the patient is receiving.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n  \n\n  \n\n  \n\n  \n\n \n\n  \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cancer-covid-19/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/06/cancer-covid.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210622T190000 DTEND;TZID=Africa/Nairobi:20210622T203000 DTSTAMP:20260424T035859 CREATED:20210530T154745Z LAST-MODIFIED:20211024T153712Z UID:5215-1624388400-1624393800@kesho-kenya.org SUMMARY:Cytoreductive Surgery (CRS) And Hyperthermic Intraperitoneal Perfusion (HIPEC) DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Mohammed Ezzi \nSponsor: RAND \nPresenters: \n\nProf Ignace De Hingh\, MD\, PhD\, Catharina Cancer Institute\, Eindhoven\, The Netherlands\nUmberto Carletti\, Clinical perfusionist\, Product Manager\,  RAND\nDr. Abdi Hakin Mohammed\, Surgical Oncologist\, and Consultant Laparoscopic Surgeon\, Mombasa.\n\nPeritoneal metastases (PM) affect hundreds of thousands of patients a year globally. The patients have a very poor prognosis\, without adequate treatment. PM is not a systemic but a regional disease\, initially regarded as untreatable\, resistant to systemic chemotherapy\, and refractory to surgery. Accumulating evidence suggests that PM can be treated by radical regional combination therapy. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal perfusion (HIPEC) is associated with significantly improved recurrence-free and overall survival in ovarian and Pseudomyxoma peritonei (PMP low-grade rare clinical condition) patients\, without increasing toxicity. CRS-HIPEC program can be safely implemented in high-volume dedicated centers\, though currently\, there is an unmet need for this technology since there is no center in Kenya offering the services.  Rand Company in Italy is producing systems for HIPEC\, which ideally should be effective\, easy to use with automatic functions\, traceable\, safe\, controlled\, and supported by clinical experts. The cost of installing the machine is on average 3.4-4 million Kenya shillings and is cost-effective since each procedure requires one kit. The machine is easy to use and any nurse can use the machine without perfusion skills. The company offers training to individuals using the machine in their respective countries.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-perfusion-hipec/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/05/cytoreductive.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210615T190000 DTEND;TZID=Africa/Nairobi:20210615T203000 DTSTAMP:20260424T035859 CREATED:20210530T154318Z LAST-MODIFIED:20211024T153841Z UID:5213-1623783600-1623789000@kesho-kenya.org SUMMARY:Colon Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Angela McLigeyo\, Physician and medical Oncologist\, JOOTRH\, Kenya \nSponsor: Beacon \nPresenters: \n\nDr. Caroline Tonio\, Consultant Physician and Medical Oncologist\, Muranga County Hospital\, Kenya.\nDr. Abdi Hakin Mohamed\, Surgical Oncologist\, and Consultant Laparoscopic Surgeon\, Mombasa.\n\nThe incidence of colorectal cancer in Africa is increasing. In Kenya\, it ranks position 5\, with the majority of patients being young (age group 41-50 years). The disease is most common in the rectum\, with a proximal anatomical distribution. The 5-year survival rate for localized cancer is 90% while for distant disease\, it’s almost 15%. Kenya has a relatively lower incidence of colorectal cancer compared to western countries with the incidence being higher in men. The major risk factors include environmental\, diet\, familial syndromes\, and inflammatory bile diseases. Mortality is associated with the male gender\, presence of comorbidity\, recurrence\, disease stage\, and receipt of chemotherapy. 8-29% of patients with colorectal cancer present with an emergency obstruction of the bowel at the time of diagnosis. Acute obstruction is associated with high morbidity and mortality. High-risk patients require regular screening. Due to late presentation\, and lack of screening capacity\, it’s difficult to detect early lesions. Consequently\, most patients end up with abdominoperineal resection with a poor prognosis. Treatment recommendation for invasive colon cancer is dependent on the pathological stage of the disease and is mainly guided by specific Biomarkers. Curative intent surgery depends on the location of the tumor and involves removing the tumor-containing a segment of the bowel with adequate margins\, by en bloc excision of the mesentery containing the feeding vessels and regional lymph nodes. Removal of as many lymph nodes as possible increases the patient’s survival. Complete mesocolic excision and 3D lymphadenectomy are associated with higher complication rates\, but no differences in post-operational mortality. They have positive effects on 5 years of overall survival and three years of disease-free survival. Additionally\, they are associated with decreased local and distant recurrences. Surveillance for stage I disease requires colonoscopy 1 year after surgery\, while stage II and III of the disease require more than just colonoscopy. Stage IV is generally incurable except in a small subset of patients with oligometastases\, where curative intent may be considered. Primary tumor sidedness has prognostic and predictive significance\, where right-sided tumors seem to be associated with inferior outcomes. Such tumors are associated with age and methylation phenotypes. Surgery in rectal cancer is very complicated because oncologists have to determine the probability of maintaining or restoring bowel functions versus anal continence and preserving genitourinary functions. Consideration is made as to whether the intention is curative or palliative. The risk of pelvic recurrence is higher in patients with rectal cancer compared to those with colon cancer\, where locally recurrent rectal cancer is associated with a poor prognosis. Enhanced Recovery After Surgery (ERAS)\, involves multimodal perioperative pathways\, which have successfully reduced in-hospital stay\, medical complications\, and costs. Laparoscopy is a minimally invasive procedure with better postoperative outcomes including reduced rates of surgical site infections\, incisional hernias\, and small bowel obstructions than ERAS. The ultimate goal of oncological surgery is an in toto resection of the primary tumor together with its entire lymphatic drainage territory to achieve low locoregional recurrence rates with long overall and disease-free survival rates. Adjuvant treatment declines with age. Currently\, neoadjuvant therapy is under consideration with very promising results. Although there is the availability of molecular testing\, high cost remains a major barrier for the patients to access the services.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/colon-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/colon-cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210610T190000 DTEND;TZID=Africa/Nairobi:20210610T203000 DTSTAMP:20260424T035859 CREATED:20210530T154028Z LAST-MODIFIED:20211024T153849Z UID:5211-1623351600-1623357000@kesho-kenya.org SUMMARY:Immunotherapies In Gastrointestinal Cancers - Focus On Esophageal And Liver Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi \nSponsor: Roche \nPresenters: Dr. Sitna Mwanzi\, Consultant Physician and Medical Oncologist\, Aga Khan Hospital\, Nairobi \nCancer immunotherapies involve harnessing cytokines\, vaccines\, cell therapy\, and immune checkpoint inhibitors to fight cancer cells. The interaction of antigen processing and presenting cells (APC) with T cells requires two costimulatory signals to activate T cells. Cytotoxic T lymphocyte antigen 4 (CTLA4) competes with CD28 for B7 on dendritic cells to prevent T cell activation. Blocking CTLA4 binding to B7 removes the inhibition\, resulting in T cell activation. Some immunotherapies target blocking PD1 from binding to PDL1\, thus restoring T cell expansion and activation. There is a need for biomarkers study to generate more data on mechanisms of interaction of host immune and tumor cells. Gastrointestinal cancers (GI) constitute ¼ of cancers diagnosed globally with colon cancer leading among the GI cancers. There is increased incidence and mortality for GI cancers. For the management of stage II and III diseases\, neoadjuvant and surgery improve survival. Additionally\, adjuvant nivolumab for one year doubles disease-free survival. In metastatic disease\, the addition of immunotherapy in the first and later lines of treatment to chemotherapy improves overall survival. Sequencing of treatments is highly recommended in the region. It is also important to consider the duration of the treatment and its accessibility by the patients. Additionally\, it is important to consider whether we can handle the associated toxicities. Assessing patients’ response to treatment using IRECIST and biomarker testing by immunohistochemistry and next-generation sequencing is recommended. The high cost of immunotherapies prevents some patients from accessing treatment. There are challenges with timely diagnosis especially in resource-constrained countries since most health facilities in Kenya lack the necessary equipment for performing Fluorescent In situ hybridization (FISH) and have to send samples for diagnosis outside the country. This comes with additional costs that most patients cannot afford. Patient selection is very important when deciding on the correct treatment since those with advanced disease may not be initiated on treatment but will instead be referred for palliative care and support.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/immunotherapy-in-gi-cancers-focus-on-esophageal-and-liver-cancers/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/immuno.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210603T190000 DTEND;TZID=Africa/Nairobi:20210603T203000 DTSTAMP:20260424T035859 CREATED:20210530T153720Z LAST-MODIFIED:20211024T153856Z UID:5209-1622746800-1622752200@kesho-kenya.org SUMMARY:Strategic Cancer Advocacy- Meaningful Engagement Of Cancer Survivors DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Muthoni Mate\, Founder Cancer Cafe \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nChristine Mugo-Sitati\, Executive director KENCO\nDr. Zipporah Ali\, Palliative Care Specialist and advocate\nBenda Kithaka\, Executive director\, Kilele health\nPhilip Odiyo\, Psycho-oncologist\, Faraja\nLivingstone Simiyu\, Lawyer and Secretary HENZO Kenya\nWanjiru Githuka\, Chairlady CSAK\n\nKenya Network of Cancer Organization (KENCO) is an umbrella body for civil society groups involved in meaningful engagement with cancer survivors. KENCO groups provide information\, education\, and screening of cancer while some member groups are involved in patient navigation to access health services. They are also involved in palliative care and advocacy\, influencing policy and representing cancer patients in government. They compliment the government in providing financial and psychosocial support to the patients\, sensitize and build capacity for the health care workers\, and provide basic information to cancer patients to ensure patient needs are met. The National Cancer Act 2012 provided a legal framework on how to deal with cancer patients. There are calls by various bodies to decentralize cancer services to the counties\, in order to ease the financial burden and to enable patients to adhere to treatment. This would greatly improve cancer services delivery in the country. The unavailability of locally generated data on cancer survivorship demonstrates the need to focus on research and clinical trials\, and to publish the research findings. Data generated from research will guide informed policy development. Public education on what services the Universal Health Care (UHC) has for cancer patients\, is a step in providing financial support to the patients\, especially since the National Hospital Insurance Funds  (NHIF)\, do not comprehensively cover cancer treatment. In addition\, private insurers and families are encouraged to supplement NHIF. Community and public engagement efforts about a healthy lifestyle and health-seeking behavior would help to reduce the number of cancer patients in the country. Additionally\, public education will help to reduce stigmatization and discrimination of cancer patients. Early diagnosis is a major challenge for childhood cancers\, due to late patient presentation. Since over 60% of children with cancer are cured with timely intervention\, there is a need for parents to be on the lookout for any abnormal signs in children.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/strategic-cancer-advocacy-meaningful-engagement-of-cancer-survivors/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/Strategic-Cancer-Advocacy.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210527T190000 DTEND;TZID=Africa/Nairobi:20210527T203000 DTSTAMP:20260424T035859 CREATED:20210530T161355Z LAST-MODIFIED:20211024T153904Z UID:5219-1622142000-1622147400@kesho-kenya.org SUMMARY:HR+/HER2-Ve Advanced Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Alice Musibi\, Assistant Professor and Medical Oncologist\, Kenyatta National Hospital \nSponsor: Novartis \nPresenters: \n\nDr. James Mbogo\, clinical oncologist working with Dr. Vj Oncology Associates based at the Nairobi West Hospital.\n\nTreatment choice for advanced breast cancer should take into account hormone receptor and HER-2 status and germline BRCA status of the patient\, in addition to PIK3CA in HR+ and PD-L1 in TNBC patients. It’s important to consider the accessibility of targeted therapies\, previous therapies\, and their toxicities. Other important factors to consider include tumor burden\, biological age\, comorbidities\, menopausal status\, need for rapid disease/ symptom control\, socioeconomic and psychological factors\, available therapies\, and patients preference. Endocrine-based therapy is preferred for hormone receptor-positive disease in patients with visceral disease. The presence of visceral crisis as a result of severe organ dysfunction can be determined by signs and symptoms\, laboratory studies\, and rapid progression of the disease. Its presence implies important visceral compromise; a clinical indication for a more rapidly efficacious therapy\, particularly because another treatment option at progression will probably not be possible. For pre-menopausal women for whom endocrine therapy was decided\, ovarian suppression/ablation (through surgery and radiation) combined with additional endocrine-based therapy is the preferred choice. Primary and secondary endocrine resistance after endocrine therapy is associated with various mechanisms. A CDK4/6 inhibitor combined with endocrine therapy is the standard of care for patients with ER+/HER-2 negative advanced breast cancers. The body composition parameters may influence prognosis in patients receiving CDK4/6 inhibitors\, whose side-effects include bone marrow toxicities\, liver enzymes\, fatigue\, pain\, skin toxicities (rashes)\, vomiting\, and neutropenia.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/hr-her2-ve-advanced-breast-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/HRHER2-ve-Advanced-Breast-Cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210520T190000 DTEND;TZID=Africa/Nairobi:20210520T203000 DTSTAMP:20260424T035859 CREATED:20210530T163719Z LAST-MODIFIED:20211024T153911Z UID:5226-1621537200-1621542600@kesho-kenya.org SUMMARY:Updates in the Management of Neuroendocrine Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Njoki Njiraini\, Resident Clinical and Radiation Oncologist at The Nairobi Hospital. Sponsor: Novartis Presenters: \n\nDr. Primus Ochieng\, Programme Director of MMed Radiation Oncology training at the University of Nairobi. He is both a Lecturer and a Consultant Clinical Oncologist at Kenyatta National Hospital\n\nNeuroendocrine tumors (NET) are a common malignant transformation of cells in the diffuse neuroendocrine system that regulates motility and secretion. The tumors are heterogeneous with a wide variety of clinical presentations and are difficult to diagnose. Neuroendocrine carcinomas are poorly differentiated with increased expression of Ki67. Most patients present with advanced disease and have a median survival of 33 months. NETs are distributed all over the body. Over 95% of NET is sporadic\, with only a small percentage being genetic-related. Currently\, there are no preventive strategies and no screening guidelines. Initially\, the classification of NET was based on the tissue of origin. To date\, WHO classification is based on grading and staging. Classification can also be based on functioning versus Non-functioning NET. Presentation is by tumor growth with pain\, obstruction hepatomegaly\, and early satiety. Diagnosis is by a systematic approach including history and physical examination\, biochemical markers\, and imaging\, although conventional imaging has a limited role in diagnosis. Chromogranin A (CgA) is a valuable diagnostic and prognostic tool that can be used to monitor treatment response. It is more sensitive than radiology for measuring progression. The major challenge with this testing method is that other conditions can cause elevated CgA and also the CgA values vary considerably between different types of NETs. The test kits are also not universally standardized. Therapies for NETs apply three principles: surgical therapy\, (best treatment option)\, symptomatic therapy\, and anti-proliferative therapy. The current focus is shifting from symptom management to targeting tumors. Chemotherapy including temozolomide and capecitabine has been shown to improve overall survival benefits\, better response\, and progression-free survival. Considering immunotherapies\, Pemblolizumab has benefits in NET tumors. Radiotherapies have palliative use. Although NETs are well managed with targeted therapy\, the technology is not currently available in Kenya. Considering limited available data\, there is a need to work in groups and generate local data on NETs.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/Management-of-Neuroendocrine-Tumors.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210513T190000 DTEND;TZID=Africa/Nairobi:20210513T203000 DTSTAMP:20260424T035859 CREATED:20210530T171047Z LAST-MODIFIED:20211024T153919Z UID:5235-1620932400-1620937800@kesho-kenya.org SUMMARY:Chronic Myeloid Leukemia (CML) Treatment In Kenya DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof. N. A. O. Abinya\, Medical Oncologist\, the Nairobi Hospital and GIPAP Physician \nSponsor: Novartis \nPresenters: \n\nDr. Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nChronic Myeloid leukemia is a cancer of bone marrow stem cells. The only known risk factors are radiation from nuclear reactors\, with no evidence of heredity risk factors. It is characterized by a translocation between chromosomes 9 and 22\, which results in an abnormal juxtaposition of two genes\, bcr\, and abl. It accounts for 15% of all leukemia cases and has an annual incidence of 1.5 cases per 100000 individuals. The median age at diagnosis is 55-65 years\, with a median survival of 3-7 years. The clinical presentation is usually massive splenomegaly\, where the disease has three phases: chronic\, accelerated\, and blast. Most patients are diagnosed in the chronic phase\, often without symptoms.  If untreated\, all patients progress to the accelerated/blast phase within 3-5 years. Diagnosis is by physical examination of the spleen and liver size\, complete blood cell count\, bone marrow aspirate for cytological examination and cytogenetic\, fluorescence in-situ hybridization\, reverse transcriptase-polymerase chain reaction (RT-qPCR). Late referrals\, inadequate infrastructure\, and trained physicians are major challenges to diagnosis. The life expectancy of newly diagnosed patients with CML in the chronic phase is now very close to age-matched individuals in the general population of Western countries. In resource-constrained countries e.g. Kenya\, the goal of treatment remains survival. The Glivec International Patient Assistance Program (GIPAP) is an international drug donation program established by Novartis Pharma AG and implemented in partnership with the Max Foundation. It has provided imatinib to eligible patients in Kenya since 2002\, at the Nairobi and the Aga Khan Hospitals for free. Patients with CML diagnosis can be referred to the GIPAP. Before imatinib was approved (FDA 2001)\, most patients were being treated with supportive care\, hydroxyurea\, interferon\, and allogeneic hematopoietic cell transplantation (“bone marrow transplant”). Today\, CML management in Kenya is mainly based on imatinib. Those failing therapies are put on second and third-generation TKIs. It’s important to check on kinase mutations that confer resistance to kinase inhibitors. Patients resistant or intolerant to imatinib can be treated with nilotinib. The main goal of treatment is to reduce the leukemic burden and the risk of progression to AP or BC. However\, if the warning signs are not recognized early\, treatment can be either a success or a failure. Molecular responses such as MMR are associated with improved survival outcomes. The major challenge with treatment is the unavailability of some drugs and high prices. Due to the COVID-19 pandemic\, there is a switch from physical to virtual review of files. The pandemic has greatly affected adherence and compliance to treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cml-treatment-in-kenya-successes-challenges/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/CML-Treatment.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210506T190000 DTEND;TZID=Africa/Nairobi:20210506T203000 DTSTAMP:20260424T035859 CREATED:20210810T102601Z LAST-MODIFIED:20220314T124351Z UID:5238-1620327600-1620333000@kesho-kenya.org SUMMARY:Optimizing Cancer Research in Kenya DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Veronica Manduku\, Radiologist at Kenya Medical Research Institute \nSponsor: Roche \nPresenters: \n\nProf. Mansour Saleh\, Chair\, Department of hematology and oncology and consultant medical oncologist\, Aga Khan University Hospital\, Nairobi.\nProf. Fredrick Chite\, CEO/Executive Director of International Cancer Institute (ICI)\nProf. N.A.O. Abinya\, Medical Oncologist\, the Nairobi Hospital and GIPAP Physician\nDr. Robai Gakunga\, Independent Research Scientist\, USIU-Africa\n\nCancer research in Kenya is mainly in the universities and is more of epidemiological studies with limited clinical research. Considering the increasing demand for cancer research in Kenya\, there is a need to develop a curriculum\, build capacity and create infrastructures to support quality research. Many drugs used in Africa are not tested in Africa\, despite research showing variations in transcriptomics for example in triple-negative breast cancer for different races. Cancer research requires a multidisciplinary approach (MDT). Funding is a major challenge in cancer research. Additionally\, managing clinical practice and research becomes difficult in Kenya where clinicians are expected to spend 100% of the time in practice\, unlike in the USA\, where there is the flexibility of working hours. In the USA\, a clinician can spend 50% of the time in clinical practice and 50% in research. In Kenya\, the workloads for doctors\, clinicians\, and lecturers are overwhelming\, with no protected time for research from the institutions. In-Africa collaborations\, as opposed to Africa-America\, and networks between clinicians\, consultants\, academic institutions\, and government agencies\, would greatly help to generate local data. Data sharing and Trust is needed and the ability to work together to accomplish a goal. The University of Nairobi has an oncology training fellowship that is helping to build capacity in the region. Commitment in science for clinicians as well as developing and reviewing protocols collectively is necessary. Considering the high cost of cancer drugs\, cancer clinical trials should seek collaborations with pharmaceutical companies. Community and patient engagement are important in clinical trials. There is a need for a data repository and registries. There is an epidemiological registry in breast cancer collected at Kenya National Hospital in collaboration with Roche. Collaborations will facilitate sharing of human resources\, infrastructure\, and samples. The literature review is equally important. The exchange program for fellows helps with gaining experience to see what other researchers are doing. Scientists are encouraged to apply for research grants\, however small. There is a need for seed funds for young investigators. Government-government collaborations are also encouraged. Research governance is necessary. in lobbying government funding\, in priority areas including the most prevalent cancers (breast cancer in women\, prostate cancer in men). \n. \n[/vc_column_text] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/optimizing-cancer-research-in-kenya/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132731.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210429T190000 DTEND;TZID=Africa/Nairobi:20210429T203000 DTSTAMP:20260424T035859 CREATED:20210810T095134Z LAST-MODIFIED:20211024T153933Z UID:5833-1619722800-1619728200@kesho-kenya.org SUMMARY:Testicular Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Glenmark \nPresenters: \n\nDr. Amina H. Kidee\, Medical Oncologist Aga Khan University Hospital\nDr. Carnjini Yogeswaran\, Consultant Urological Surgeon\, Aga Khan University Hospital\n\nTesticular cancer (TC) accounts for less than 1% of adult neoplasms and 5% of urological tumors.  It’s the most commonly diagnosed cancer in young men (20-34 years)\, and the incidence is increasing in industrialized countries.\, but there is a need for local data to determine incidence in Africa. It is predicted that the survival rate in Kenya is low since the disease is not diagnosed early.  The risk factors for TC oncogenesis include cryptorchidism\, history of subfertility\, contralateral history of testicular cancer\, history of germ cell neoplasm in situ\, family history of TC\, race\, age\, and HIV. Individuals at high risk should be informed about the importance of physical self-examination. WHO classification of TC is based on the tumor origin\, and the presentation may be localized or disseminated. Diagnosis is by history\, examination\, imaging\, and serum tumor markers used for prognosis and staging.  Transcrotal ultrasound with Doppler is performed to confirm a testicular mass\, to determine whether a mass is intra or extra testicular\, and to explore the contralateral testis. Transscrotal biopsies of the testes should not be performed because of the risk of tumor cells seeding of the inguinal and pelvic lymphatic drainage. The biopsy is also of limited value because testicular germ cell tumors are heterogeneous. Management of the disease requires an integrated multidisciplinary team (MDT). Removal of the entire organ is necessary to properly identify the histologic type(s) present and to select the appropriate therapy. Radical inguinal Orchidectomy is the standard of care and involves the division of the spermatic cord at the internal inguinal ring. The scrotal approach should be avoided. Chemotherapy should be initiated prior to orchidectomy where applicable\, to control the disease and stabilize the patient. Testis sparing surgery aims to preserve fertility and hormonal functions. Patients should be counseled and be informed of the risk of local recurrence which is 8%. The testicular prosthesis should be offered to all patients undergoing unilateral or bilateral orchidectomy. It can be inserted at orchidectomy or subsequently. Contralateral testicular biopsy should be offered to high-risk patients. Semen abnormalities occur in 24-50% of TC patients even prior to orchidectomy. Additionally\, chemotherapy and radiotherapy can impair fertility. Semen preservation by sperm banking (cryopreservation) should be offered to all patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/testicular-cancer/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132749.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210318T190000 DTEND;TZID=Africa/Nairobi:20210318T203000 DTSTAMP:20260424T035859 CREATED:20210810T093714Z LAST-MODIFIED:20211024T153940Z UID:5829-1616094000-1616099400@kesho-kenya.org SUMMARY:Rectal Cancer – Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Njoki Njiraini \nSponsor: Roche \nPresenters: \n\nDr. Anthony Ndiritu\, Consultant Clinical Oncologist\, Kenyatta National Hospital (KNH)\nDr. Alex Muturi\, Consultant General Surgeon & Endoscopist\, Kenyatta University Teaching Referral and Research Hospital (KUTRRH)\n\nManagement of colorectal cancer requires staging and risk assessment by a multidisciplinary team (MDT) to help in decision making and to audit and review the outcomes. Nutrition therapists are part of the MDT as the patients need to be nutritionally optimal before chemoradiotherapy and surgery for them to tolerate the effects of the treatment. Colorectal cancer is preventable and treatable if detected early. Early screening using immunochemical testing would help to pick the lesions when they are precancerous\, thus reducing cancer-related death by between 40-60%. A low index of suspicion of colorectal cancer among the caregivers is a major hindrance to timely diagnosis. For example\, patients with bloody stool may be treated for hemorrhage or other infections\, due to low suspicion of colorectal cancer. An accurate diagnosis would require a colonoscopy. Traditional\, extensive lymph node dissection with limited use of neoadjuvant radio is falling out of favor\, due to high functional genitourinary impairments and the need for experienced individuals to perform adequate dissection for outcomes. There is evidence that the dissection has similar recurrent rates as with neoadjuvant. Surgical site infections are a major challenge to surgery and require management. The cost of screening in Kenya is Ksh. 1000-2500. Management of colorectal cancer is by chemoradiation followed by surgery. The decision to take short-course radiotherapy (within a week) as opposed to the long course (5 to 6 weeks) should be guided by MDT. Patients with complete clinical response to chemoradiotherapy but who refuse to take surgery are at higher risk of local failure.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/rectal-cancer-multidisciplinary-approach/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132818.jpg END:VEVENT END:VCALENDAR